Trilaciclib: Difference between revisions

Browse history interactively

← Previous edit Next edit →

Content deleted Content added

VisualWikitext

Revision as of 20:16, 22 November 2023 edit Vaccinationist (talk \| contribs) Extended confirmed users 4,704 edits m category Tag: 2017 wikitext editor ← Previous edit		Revision as of 16:57, 6 June 2024 edit undo Marbletan (talk \| contribs) Extended confirmed users 3,866 edits no longer a stub Next edit →
(2 intermediate revisions by 2 users not shown)
Line 1: {{~~short~~Short description\|Chemical compound}} {{Use American English\|date=February 2021}} {{Use dmy dates\|date=February 2021}} {{Infobox drug ~~\| drug_name =~~ ~~\| INN =~~ ~~\| type = <!-- empty -->~~ \| image = Trilaciclib.svg \| width = Line 16 ⟶ 13: \| Drugs.com = {{drugs.com\|pro\|Cosela}} \| MedlinePlus = ~~\| licence_EU = <!-- EMA uses INN (or special INN_EMA) -->~~ \| DailyMedID = Trilaciclib ~~\| licence_US = <!-- FDA may use generic or brand name (generic name preferred) -->~~ \| pregnancy_AUえーゆー = <!-- A / B1 / B2 / B3 / C / D / X --> \| pregnancy_AUえーゆー_comment = \| pregnancy_category= ~~\| dependency_liability =~~ ~~\| addiction_liability =~~ \| routes_of_administration = [[Intravenous]] \| class = [[CDK inhibitor\|Cyclin-dependent kinase (CDK) inhibitor]] ~~\| ATCvet =~~ \| ATC_prefix = V03 \| ATC_suffix = AF12 Line 124 ⟶ 116: == External links == * {{cite web \| url = https://druginfo.nlm.nih.gov/drugportal/name/trilaciclib \| publisher = U.S. National Library of Medicine \| work = Drug Information Portal \| title = Trilaciclib }} * {{ClinicalTrialsGov\|NCT03041311\|Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Extensive Stage Small Cell Lung Cancer (SCLC)}} * {{ClinicalTrialsGov\|NCT02499770\|Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)}} * {{ClinicalTrialsGov\|NCT02514447\|Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy}} {{Detoxifying agents for antineoplastic treatment}} ~~{{Targeted cancer therapeutic agents}}~~ {{Portal bar \| Medicine}} ~~[[Category:Breakthrough therapy]]~~ [[Category:Protein kinase inhibitors]] [[Category:Chemotherapeutic adjuvants]] Line 141 ⟶ 131: [[Category:Guanidines]] [[Category:CDK inhibitors]] ~~{{Pharma-stub}}~~